Navigation Links
Reportlinker Adds Threats to Avastin - Targeting the VEGF Pathway
Date:8/31/2010

NEW YORK, Aug. 31 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Threats to Avastin - Targeting the VEGF Pathway http://www.reportlinker.com/p0196624/Threats-to-Avastin---Targeting-the-VEGF-Pathway-.html

Avastin is set to become the most successful cancer treatment to date and one of the leading drugs with sales likely to exceed US$9 billion by 2015.

Since its launch in 2004, Avastin has achieved strong growth culminating in sales of US$5,731 million (SFr 6.2 billion) in 2009. Not only is Avastin now Roche's top-selling oncology product, ahead of both MabThera/Rituxan (rituximab) and Herceptin (trastuzumab), but its sales exceed those of every other cancer product on the market.

In 2009, solid growth was seen across all markets, driven by continued uptake in colorectal cancer (CRC), breast cancer (BC) and non-small cell lung cancer (NSCLC). In the US, metastatic BC was the main growth driver, helped by launches for the new indications of glioblastoma and renal cell carcinoma (RCC). Strong growth was seen in the EU in all indications. In the Japanese market, Avastin sales growth was particularly strong with continued substantial uptake in CRC, enhanced by its recent approval for NSCLC.

While its first-to-market status and Roche's experience in the oncology sector have provided a sound basis for growth, a number of related angiogenesis products have been launched and many more are on the horizon. What threat do they present to Avastin's status and when will their impact be felt?

The current market

Avastin is the only product that currently directly inhibits VEGF. Competing products take a different approach. Bayer/Onyx Nexavar, Pfizer's Sutent and GSK's V
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015
2. Reportlinker Adds Epigenetics: Current and future applications that are driving novel drug discovery
3. Reportlinker Adds Clinical Laboratory Testing Volume 1: Reagents and Instruments
4. Reportlinker Adds Portable and Transport Ventilator Market Shares, Strategies, and Forecasts, Worldwide, 2010 to 2016
5. Reportlinker Adds Pharmaceutical M&A in the Asia-Pacific Region - India and China drive regional activity but Japan still dominates high value transactions
6. Reportlinker Adds Strategic Analysis of End-user Preferences in the U.S. Stem Cell Research Tools Markets
7. Reportlinker Adds Production and Market of Xylose in China
8. Reportlinker Adds Advances in Large Scale BioManufacturing and Scale-Up Production, 2nd ED
9. Reportlinker Adds European Markets for Small Joint Reconstructive Devices 2010 (15 Countries)
10. Reportlinker Adds Japanese Market for Small Joint Reconstructive Devices 2010
11. Reportlinker Adds Effective Social Media Marketing Strategies for Pharmaceutical Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  Drug delivery technologies that ... essential part of the entire drug development process. ... in new vaccine delivery technologies in a bid ... skin delivery procedures. New analysis from ... though the needle-free delivery sector currently makes up ...
(Date:9/2/2014)... COSTA MESA, Calif. , Sept. 2, 2014 ... organization was just recognized as one of the ... Over the past few years, the company has ... phase clinical research, late phase global clinical development, ... the past 2 years, WCCT Global has successfully ...
(Date:9/1/2014)... YORK , Sept. 1, 2014 ... market research report is available in its catalogue: ... 2014 - 2024 http://www.reportlinker.com/p02280919/Antibody-Drug-Conjugates-Market-2nd-Edition-2014---2024.html ... (ADCs) are a new class of therapeutic agents, ... pharmaceutical companies. Generally addressed as the marriage of ...
Breaking Medicine Technology:Needle-Free Delivery Devices Shape the Future of Vaccines, Says Frost & Sullivan 2Needle-Free Delivery Devices Shape the Future of Vaccines, Says Frost & Sullivan 3Contract Research Organization WCCT Global Celebrates Being Named as One of the Fastest Growing Companies in America 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 3Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 4Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 5Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 6Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 7Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 8Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 10Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 11Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 12Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 13Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 14Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 15Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 16Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 17Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 18
... USCAP MeetingSOUTH SAN FRANCISCO, Calif., March 13 Rigel ... the enrollment of the first patient in a Phase ... patients with refractory or relapsed peripheral T-cell lymphoma (PTCL). ... the efficacy of R788, an orally bio-available Syk kinase ...
... Phase II Study Published in The Lancet of Fast-Tracked ... Minor Bleeding and was Well Tolerated When Given With ... a Schering-Plough Corporation (NYSE: SGP ) Phase ... receptor antagonist (TRA), were published today in The ...
Cached Medicine Technology:Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas 2Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas 3Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 2Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 3Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 4Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 5Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 6Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 7
(Date:9/2/2014)... The Jerry Segal Classic to benefit ... 19 at The ACE Club and Green Valley Country ... years, the Classic, organized by the Friends of Jerry ... and services designed to support patients and their families ... “The Segal Classic is a labor of love, my ...
(Date:9/2/2014)... Port Washington, New York (PRWEB) September 02, 2014 ... Waichman LLP announces that Class Counsel has ... and for service awards in the class action ... to Parker Waichman LLP, the Court-Appointed Class Counsel ... Cabraser Heimann & Bernstein, LLP; Audet & Partners, ...
(Date:9/2/2014)... 2014 Lseat.com is one of the most ... its products are user-friendly items; no professional installation is required. ... they can slip right over the cars’ seats. That can ... website is filled with various kinds of practical covers. ... of Jeep leather seat covers . Also, the company ...
(Date:9/2/2014)... California (PRWEB) September 02, 2014 The ... reach USD 8,918.8 million by 2020, growing at an ... to a new study by Grand View Research, Inc. ... and plague modification devices are used for treating peripheral ... formation of atherosclerotic plaques in arteries. These devices are ...
(Date:9/2/2014)... 2014 Eric Jimenez and Leah Ashley ... a revolutionary makeup application device. Designed to improve and ... in the palm of women’s hands to help them ... Color Me’s success lies in its patented technology. With ... of 15,000 pulses per minute, the device applies foundation ...
Breaking Medicine News(10 mins):Health News:The 25th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:A Proposed Order Has Been Submitted in A Class Action Law Suit Brought Over Flushmate Toilets, Parker Waichman Announces 2Health News:A Proposed Order Has Been Submitted in A Class Action Law Suit Brought Over Flushmate Toilets, Parker Waichman Announces 3Health News:High Quality 1997-2006 JEEP Wrangler TJ Leather Seat Covers From Popular Supplier Lseat.com 2Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 2Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 3Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 4Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 5Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 2Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 3
... a story that continues,to captivate millions of Americans ... transplants, golfer and double heart transplant,recipient Erik Compton ... as he pursues his quest to qualify for ... in Brooksville, Florida., (Photo: http://www.newscom.com/cgi-bin/prnh/20081112/CLW035 ...
... Quantum Group,Inc. (Amex: QGP ) (http://www.QuantumMD.com ... of a scheduled presentation to be,delivered at Paulson ... J. Guillama later this morning, announced today that,it ... 3,650 using the community,health systems (CHS) established by ...
... Infection, LANSING, Mich., Nov. 12 For those ... and flu season, there,s yet another reason to,choose cherries, ... typical flu vaccine, a new study suggests quercetin, a ... in a,variety of fruits and vegetables, including tart cherries, ...
... an early,stage company developing an implantable neuromodulation system ... has closed a licensing,and financing deal, led by ... Existing investor, Greatbatch, Inc. (NYSE: GB ), ... that will provide between,$11 million and $13.5 million ...
... High-Quality Emergency,Healthcare to Rural Areas, NEW YORK, ... announced that it has been selected by Ameya,Preserve ... supplier for each,of the 300 new homes built ... the first of its kind in the United ...
... is facing a medical liability crisis which has,resulted in ... Pacific Research Institute (a not for profit, nonpartisan,organization), was ... total,cost of tort litigation in our country. They have ... due to lawsuit abuse totals $589,billion each year., ...
Cached Medicine News:Health News:Millions Follow Erik Compton's Quest to Win a PGA TOUR Card and Build Awareness for Organ Donation 2Health News:Millions Follow Erik Compton's Quest to Win a PGA TOUR Card and Build Awareness for Organ Donation 3Health News:The Quantum Group Announces Continued Growth of Patient Base and Preliminary Revenue Guidance 2Health News:The Quantum Group Announces Continued Growth of Patient Base and Preliminary Revenue Guidance 3Health News:The Quantum Group Announces Continued Growth of Patient Base and Preliminary Revenue Guidance 4Health News:New Research Shows Specific Antioxidant, Found in Cherries, May Boost the Body's Defenses Against the Flu 2Health News:Intelect Medical Closes $11 Million in Funding from Boston Scientific and Greatbatch for Stroke and TBI Recovery Clinical Trials 2Health News:Intelect Medical Closes $11 Million in Funding from Boston Scientific and Greatbatch for Stroke and TBI Recovery Clinical Trials 3Health News:Intelect Medical Closes $11 Million in Funding from Boston Scientific and Greatbatch for Stroke and TBI Recovery Clinical Trials 4Health News:SwiftMD to Provide Telemedicine Services to New Montana Development 2Health News:SwiftMD to Provide Telemedicine Services to New Montana Development 3Health News:How Texas Cured Its Doctor Shortage and Became a Model for Healthcare Reform 2Health News:How Texas Cured Its Doctor Shortage and Became a Model for Healthcare Reform 3
Multi-frequency, HST, linear transducer with a longer (60mm) footprint. Available with puncture adapter and water path. This transducer incorporates ALOKAs exclusive Hemispheric Sound Technology and ...
Multi-frequency, Super High Density, linear transducer with a longer (60mm) footprint. Available with puncture adapter and water path....
... high frequency (13Mhz) ... and superficial imaging. ... Hemispheric Sound Technology ... This multi-frequency transducer ...
This versatile convex array abdominal transducer is multi-frequency, offering 5 levels of fundamental frequencies in addition to 4 settings of Harmonic frequencies. This transducer provides superb im...
Medicine Products: